Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

473.04 -0.75 (-0.16%)
Streaming Delayed Price Updated: 10:38 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease ↗
FDA approves Novo Nordisk's Wegovy for MASH with liver fibrosis, supported by ESSENCE trial data as the company projects lower 2025 sales growth. 
Via Benzinga
News headline image
Billionaire Investor Buys Google And This Gold Miner Stock ↗
John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet. 
Via Benzinga
News headline image
Madrigal (MDGL) Q2 Revenue Soars 1,313% ↗
Via The Motley Fool
News headline image
Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Beats Q2 2025 Revenue Estimates and Narrows Losses on Strong Rezdiffra Sales ↗
Madrigal Pharmaceuticals (MDGL) beats Q2 2025 revenue estimates with $212.8M, driven by strong Rezdiffra sales, narrowing losses. Stock rises 12.8% pre-market. 
Via Chartmill
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Soaring Today ↗
Via The Motley Fool
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Is Sinking Today ↗
Via The Motley Fool
News headline image
Earnings Preview For Madrigal Pharmaceuticals ↗
 
Via Benzinga
News headline image
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug ↗
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August. 
Via Benzinga
News headline image
5 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years ↗
Via The Motley Fool
News headline image
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock ↗
Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment,... 
Via Stocktwits
Topics Death
News headline image
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Workday, ACM Research, ZoomInfo Technologies, CEVA, Intuit And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis ↗
Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations. 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week ↗
Via The Motley Fool
News headline image
Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease. 
Via MarketBeat
News headline image
Top 3 Health Care Stocks That May Dip This Month ↗
 
Via Benzinga
News headline image
Billionaire Ken Griffin Invested $93 Million of Citadel's Portfolio in a Stock That Could Rocket 105% Higher, According to a Wall Street Analyst ↗
Via The Motley Fool
News headline image
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move ↗
Via The Motley Fool
News headline image
MDGL: A Promising Play In The Weight Loss Drug Space ↗
The launch of Madrigal Pharmaceuticals Inc.’s NASH drug Rezdiffra exceeded all expectations in the recent quarterly earnings release. The stock rose more than 50% in a few days – and the company now... 
Via Talk Markets
Topics Stocks / Equities
News headline image
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More ↗
There's a bright future ahead for this company. 
Via The Motley Fool
News headline image
Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗
Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%). 
Via Benzinga
News headline image
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH ↗
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.